Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Using genetic screening, scientists have found a new drug combination that works against some treatment-resistant lung, brain ...

Lung cancer doesn’t just come from smoking. The amount of ultraprocessed food a person eats and drinks could be connected ...

New research identifies NF-kappa-B-activating protein-like (NKAPL) as a potent tumor suppressor in non-small cell lung cancer ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.

Biodesix Inc. (NASDAQ:BDSX) is one of the best penny stocks under $1 to buy now. On June 10, Biodesix announced a new partnership with the Association of Pulmonary Advanced Practice Providers/APAPP.

Australian researchers have discovered a promising new strategy to suppress the growth of aggressive and hard-to-treat ...